Verismo Therapeutics Announces Strategic Partnership with IFLI to Support SynKIR™-310 Development in Follicular Lymphoma - Thailand PR News

 - [Banking](https://thailandbusinessnews.net/category/banking/)
- [Companies](https://thailandbusinessnews.net/category/companies/)
- [Economy](https://thailandbusinessnews.net/category/economy/)
- [Press Releases](https://thailandbusinessnews.net/category/press-release/)
    - [PR Newswire](https://thailandbusinessnews.net/pr-newswire-updates/)
- [Tech](https://thailandbusinessnews.net/category/tech/)
- [Tourism](https://thailandbusinessnews.net/category/tourism/)

    - [Press Release](https://thailandbusinessnews.net/category/press-release/)

# Verismo Therapeutics Announces Strategic Partnership with IFLI to Support SynKIR™-310 Development in Follicular Lymphoma

   #####  Up next

  ###### [GORTEC Announces New Trial Success for Head and Neck Cancer Treatment](https://thailandbusinessnews.net/press-release/gortec-announces-new-trial-success-for-head-and-neck-cancer-treatment/)

  Published on 07 January 2025 #####  Author

#####   [ CISION PRNewswire ](https://thailandbusinessnews.net/author/cision/)

  ##### Tags

- [PRNewswire](https://thailandbusinessnews.net/tag/prnewswire/)

 ![](https://mma.prnasia.com/media2/2591702/Verismo_Therapeutics_IFLI_Logo.jpg?p=medium600 "logo") ![](https://mma.prnasia.com/media2/1881639/Verismo_2022_Logo.jpg?p=medium600 "logo") Verismo will receive up to $4.05 million USD in investments from the Institute for Follicular Lymphoma Innovation (IFLI). The partnership with IFLI will accelerate the clinical development of SynKIR™-310 in Follicular Lymphoma (FL) by leveraging IFLI’s expertise and network, expanding clinical sites, and increasing patient enrollment.

PHILADELPHIA, Jan. 7, 2025 /PRNewswire/ — [Verismo Therapeutics](https://c212.net/c/link/?t=0&l=en&o=4334613-1&h=3908115556&u=https%3A%2F%2Fverismotherapeutics.com%2F&a=Verismo+Therapeutics), a clinical-stage biotechnology company developing the novel KIR-CAR platform for solid tumors and blood cancers, today announced a strategic investment from the [Institute for Follicular Lymphoma Innovation](https://c212.net/c/link/?t=0&l=en&o=4334613-1&h=3949231841&u=https%3A%2F%2Fwww.i-fli.org%2F&a=Institute+for+Follicular+Lymphoma+Innovation) (IFLI), a global non-profit foundation dedicated to advancing treatment options for follicular lymphoma (FL). This partnership aims to enhance Verismo’s SynKIR™-310 pipeline and provide catalytic investment for the pipeline’s FL arm, accelerating the development of next-generation cell therapies that address high unmet medical needs.

The investment from IFLI will help advance Verismo’s SynKIR™-310 pipeline, which aims to treat FL along with other non-Hodgkin lymphoma (NHL) subtypes. IFLI’s deep expertise in FL will be crucial in guiding Verismo through FL-specific clinical considerations and aiding in patient recruitment.

"We are thrilled to receive this strategic investment from IFLI, which shares our vision for developing transformative therapies for patients suffering from aggressive tumors and lymphomas," said Bryan Kim, CEO of Verismo Therapeutics. "This funding will enable us to expedite the clinical development of our SynKIR™-310 program, which is currently in Phase 1 clinical trial. IFLI’s support will enable us to bring our novel therapies to FL patients more quickly and efficiently."

Verismo Therapeutics is currently running a multicenter, open-label study of a single infusion of SynKIR™-310 in participants with post-CAR T and CAR-naive relapsed/refractory B-NHL ([NCT06544265](https://c212.net/c/link/?t=0&l=en&o=4334613-1&h=1061806259&u=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06544265&a=NCT06544265)), including FL. This clinical study is a basket trial in B-NHL subtypes. The design includes two dose levels and an expansion cohort at the Recommended Phase 2 Dose (RP2D), with a total enrollment of up to 18 patients. With IFLI’s investment totaling up to $4,050,000 over 3 years, Verismo aims to expand the number of FL-focused clinical sites to enroll more FL patients.

"IFLI is excited to support the next wave of transformative cell therapies with Verismo lead SynKIR™-310 targeting CD19," said Michel Azoulay, MD, MBA, Chief Medical Officer of IFLI. "We expect that positive Phase 1safety and preliminary efficacy data will support accelerated clinical development in FL for patients not responding to first line immunotherapy as well as exploration in additional NHL."

IFLI has a proven track record of advancing lymphoma treatments through strategic funding and collaborative partnerships, including its support for groundbreaking research at Washington University in St. Louis, which leverages ctDNA sequencing to improve the understanding and treatment of FL.

For more information on Verismo Therapeutics, visit [verismotherapeutics.com](https://c212.net/c/link/?t=0&l=en&o=4334613-1&h=1840425463&u=https%3A%2F%2Fverismotherapeutics.com%2F&a=verismotherapeutics.com), and for more information on IFLI, visit [www.i-fli.org](https://c212.net/c/link/?t=0&l=en&o=4334613-1&h=3722111553&u=https%3A%2F%2Fwww.i-fli.org%2F&a=www.i-fli.org).

About the Institute for Follicular Lymphoma Innovation

The Institute for Follicular Lymphoma Innovation (IFLI) is a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL). IFLI supports cutting-edge research and technology to lead to the development and commercialization of novel therapeutics and/or biomarkers for the treatment of FL, and to understand the biology of FL. The foundation deploys its budget across grants, project-based partnerships, and venture philanthropic investments to achieve its innovation goals. IFLI promotes collaboration and works to enable data sharing and the exchange of knowledge and expertise among researchers and institutions advancing FL research. Learn more at [www.i-fli.org](https://c212.net/c/link/?t=0&l=en&o=4334613-1&h=3722111553&u=https%3A%2F%2Fwww.i-fli.org%2F&a=www.i-fli.org)

About Verismo Therapeutics

Verismo Therapeutics, a subsidiary of HLB Innovation, is a pioneer in multi-chain KIR-CAR technology, with its first assets SynKIR™-110 and SynKIR™-310 currently in Phase 1 clinical trials. Verismo is the only company developing the KIR-CAR platform, using a modified NK cell derived receptor and DAP12 pairing, designed to improve persistence and efficacy against aggressive tumors. The KIR-CAR platform technology was developed specifically to address areas of high unmet medical need, including advanced solid tumors and B cell associated disorders and malignancies. For more information, visit: [www.verismotherapeutics.com](https://c212.net/c/link/?t=0&l=en&o=4334613-1&h=809766580&u=http%3A%2F%2Fwww.verismotherapeutics.com%2F&a=www.verismotherapeutics.com)

About the KIR-CAR Platform

The KIR-CAR platform is a multi-chain CAR T cell therapy and has been shown in preclinical animal models to be capable of maintaining antitumor T cell activity even in challenging tumor microenvironments. Using NK cell derived KIR and DAP12 split signaling provides a novel combined activation and co-stimulation separate from the usual T cell stimulation pathways. It also enables sustained chimeric receptor expression and improves KIR-CAR T cell long term function. This results in prolonged T cell functional persistence and leads to regression of solid tumors in preclinical models that are resistant to traditional CAR T cell therapies.

Forward Looking Statements

This press release contains forward-looking statements, including, but are not limited to, those statements regarding our expectations for the timing, progress, and results of clinical trials; potential regulatory approvals; anticipated benefits, safety, and efficacy of our product candidates; our product development strategies; and other statements that are not historical facts. These forward-looking statements are based on our current expectations and are subject to numerous risks and uncertainties that could cause actual outcomes to differ materially. Important factors that could cause actual results to differ include, among others, risks related to clinical trials, regulatory processes, market acceptance, financial projections, and our ability to successfully develop and commercialize our product candidates. Forward-looking statements in this release represent our beliefs and assumptions only as of the date hereof, and we expressly disclaim any obligation to update these statements as new information becomes available, except as required by law.

Media Contact, Verismo Therapeutics Pavel Aprelev<Pavel.Aprelev@verismotherapeutics.com>

Media Contact, IFLILaura DiCaprioMcDougall Communications<laura@mcdougallpr.com>+1 (585) 434-2153

[Source link ](https://www.prnasia.com/story/archive/4589944_AE89944_0?rand=89749)

```
This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network
```

  #####  You May Also Like

  [](https://thailandbusinessnews.net/press-release/beyond-claims-how-kuky-helps-health-insurers-enhance-community-well-being/) ## Beyond Claims: How Kuky Helps Health Insurers Enhance Community Well-Being

  SYDNEY, March 14, 2025 /PRNewswire/ — In 2022-23, Australia spent more than…

- [CISION PRNewswire](https://thailandbusinessnews.net/author/cision/ "View all posts by CISION PRNewswire")
- March 14, 2025

   [](https://thailandbusinessnews.net/press-release/digift-closes-strategic-round-to-scale-institutional-grade-rwa-infrastructure-securing-us25-million-to-date/) ![DigiFT Closes Strategic Round to Scale Institutional-Grade RWA Infrastructure, Securing US Million to Date](https://i0.wp.com/r2.thailandbusinessnews.net/2025/08/DigiFT_Logo.jpg?resize=260%2C140&ssl=1 "DigiFT Closes Strategic Round to Scale Institutional-Grade RWA Infrastructure, Securing US Million to Date")

- [Press Release](https://thailandbusinessnews.net/category/press-release/)

 ## DigiFT Closes Strategic Round to Scale Institutional-Grade RWA Infrastructure, Securing US$25 Million to Date

  SINGAPORE, Aug. 21, 2025 /PRNewswire/ — DigiFT, a licensed exchange purpose-built for…

- [CISION PRNewswire](https://thailandbusinessnews.net/author/cision/ "View all posts by CISION PRNewswire")
- August 21, 2025

   [](https://thailandbusinessnews.net/press-release/china-southern-power-grid-showcases-ai-innovations-at-world-ai-conference/) ![China Southern Power Grid Showcases AI Innovations at World AI Conference](https://i0.wp.com/mmx.prnasia.com/media/MS1888541/20260721040736EDT_image_1.jpg?resize=260%2C140&ssl=1 "China Southern Power Grid Showcases AI Innovations at World AI Conference")

- [Press Release](https://thailandbusinessnews.net/category/press-release/)

 ## China Southern Power Grid Showcases AI Innovations at World AI Conference

  SHANGHAI, July 22, 2026 /PRNewswire/ — China Southern Power Grid (CSG) showcased…

- [CISION PRNewswire](https://thailandbusinessnews.net/author/cision/ "View all posts by CISION PRNewswire")
- July 22, 2026

 ##### Most Read

- [![Finloop Raises Over US$10 Million in Series A+ Financing, Welcomes HSBC as One of its Strategic Investors, and Launches Its Corporate Service "Finterprise"](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/finloop-raises-over-us10-million-in-series-a-financing-welcomes-hsbc-as-one-of-its-strategic-investors-and-launches-its-corporate-service-finterprise/ "Finloop Raises Over US$10 Million in Series A+ Financing, Welcomes HSBC as One of its Strategic Investors, and Launches Its Corporate Service "Finterprise"") [Finloop Raises Over US$10 Million in Series A+ Financing, Welcomes HSBC as One of its Strategic Investors, and Launches Its Corporate Service "Finterprise"](https://thailandbusinessnews.net/press-release/finloop-raises-over-us10-million-in-series-a-financing-welcomes-hsbc-as-one-of-its-strategic-investors-and-launches-its-corporate-service-finterprise/ "Finloop Raises Over US$10 Million in Series A+ Financing, Welcomes HSBC as One of its Strategic Investors, and Launches Its Corporate Service "Finterprise"")
- [![Chubb Wealth Debuts Evergreen Private Markets Fund Series with S64](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/chubb-wealth-debuts-evergreen-private-markets-fund-series-with-s64/ "Chubb Wealth Debuts Evergreen Private Markets Fund Series with S64") [Chubb Wealth Debuts Evergreen Private Markets Fund Series with S64](https://thailandbusinessnews.net/press-release/chubb-wealth-debuts-evergreen-private-markets-fund-series-with-s64/ "Chubb Wealth Debuts Evergreen Private Markets Fund Series with S64")
- [![Triton Uranium Advances Atlas Project, Reports Exploration Target of 46.56 Million Pounds of Uranium](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/triton-uranium-advances-atlas-project-reports-exploration-target-of-46-56-million-pounds-of-uranium/ "Triton Uranium Advances Atlas Project, Reports Exploration Target of 46.56 Million Pounds of Uranium") [Triton Uranium Advances Atlas Project, Reports Exploration Target of 46.56 Million Pounds of Uranium](https://thailandbusinessnews.net/press-release/triton-uranium-advances-atlas-project-reports-exploration-target-of-46-56-million-pounds-of-uranium/ "Triton Uranium Advances Atlas Project, Reports Exploration Target of 46.56 Million Pounds of Uranium")
- [![Adecco Group announces Salesforce's Agentforce Coworker rollout across 40 countries](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/adecco-group-announces-salesforces-agentforce-coworker-rollout-across-40-countries/ "Adecco Group announces Salesforce's Agentforce Coworker rollout across 40 countries") [Adecco Group announces Salesforce's Agentforce Coworker rollout across 40 countries](https://thailandbusinessnews.net/press-release/adecco-group-announces-salesforces-agentforce-coworker-rollout-across-40-countries/ "Adecco Group announces Salesforce's Agentforce Coworker rollout across 40 countries")
- [![GCCL and Medicover Integrated Clinical Services Announce Strategic Collaboration to Strengthen Multinational Clinical Trial Services](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/gccl-and-medicover-integrated-clinical-services-announce-strategic-collaboration-to-strengthen-multinational-clinical-trial-services/ "GCCL and Medicover Integrated Clinical Services Announce Strategic Collaboration to Strengthen Multinational Clinical Trial Services") [GCCL and Medicover Integrated Clinical Services Announce Strategic Collaboration to Strengthen Multinational Clinical Trial Services](https://thailandbusinessnews.net/press-release/gccl-and-medicover-integrated-clinical-services-announce-strategic-collaboration-to-strengthen-multinational-clinical-trial-services/ "GCCL and Medicover Integrated Clinical Services Announce Strategic Collaboration to Strengthen Multinational Clinical Trial Services")
- [![600 Clubs Strong: Inspire Brands Asia Continues Regional Expansion, Affirms Vision for 1,000 by 2028](https://secure.gravatar.com/avatar/96e712b5408b51145de772098c3ff3417ce8a11555b7c388d84204c5769f5631?s=40&d=blank&r=g)](https://thailandbusinessnews.net/press-release/600-clubs-strong-inspire-brands-asia-continues-regional-expansion-affirms-vision-for-1000-by-2028/ "600 Clubs Strong: Inspire Brands Asia Continues Regional Expansion, Affirms Vision for 1,000 by 2028") [600 Clubs Strong: Inspire Brands Asia Continues Regional Expansion, Affirms Vision for 1,000 by 2028](https://thailandbusinessnews.net/press-release/600-clubs-strong-inspire-brands-asia-continues-regional-expansion-affirms-vision-for-1000-by-2028/ "600 Clubs Strong: Inspire Brands Asia Continues Regional Expansion, Affirms Vision for 1,000 by 2028")

##### Subscribe via Email

 Enter your email address to subscribe and receive notifications of new posts by email.

  Email Address

       Subscribe

  [](https://thailandbusinessnews.net/press-release/a-robust-adjusted-ebit-margin-of-18-8-driven-by-solid-organic-revenue-growth-of-7-4/) ![A robust adjusted EBIT margin of 18.8%, driven by solid organic revenue growth of 7.4%](https://i0.wp.com/mmx.prnasia.com/media/MS1988977/VBD_01.jpg?resize=260%2C140&ssl=1 "A robust adjusted EBIT margin of 18.8%, driven by solid organic revenue growth of 7.4%")

 ## A robust adjusted EBIT margin of 18.8%, driven by solid organic revenue growth of 7.4%

  PARIS, Sept. 18, 2026 /PRNewswire/ — Virbac Headquarters, Carros, France H1…

   [](https://thailandbusinessnews.net/press-release/banyan-group-announces-acquisition-of-newmark-hotels-reserves-adding-26-hotels-lodges-and-reserves-across-seven-african-countries/) ![Banyan Group Announces Acquisition of Newmark Hotels & Reserves, Adding 26 Hotels, Lodges, and Reserves Across Seven African Countries](https://i0.wp.com/mmx.prnasia.com/media/MS1990742/20260917065723EDT_image_1.jpg?resize=260%2C140&ssl=1 "Banyan Group Announces Acquisition of Newmark Hotels & Reserves, Adding 26 Hotels, Lodges, and Reserves Across Seven African Countries")

 ## Banyan Group Announces Acquisition of Newmark Hotels &amp; Reserves, Adding 26 Hotels, Lodges, and Reserves Across Seven African Countries

  Newmark’s deep regional expertise across urban, nature and wildlife hospitality…

   [](https://thailandbusinessnews.net/press-release/xpeng-launches-its-next-gen-ai-flagship-suv-g9l-in-china-with-global-launch-set-for-oct-12-at-the-paris-motor-show/) ![XPENG Launches Its Next-Gen AI Flagship SUV G9L in China, with Global Launch Set for Oct 12 at the Paris Motor Show](https://i0.wp.com/mmx.prnasia.com/media/MS1990789/20260917090347EDT_image_1.jpg?resize=260%2C140&ssl=1 "XPENG Launches Its Next-Gen AI Flagship SUV G9L in China, with Global Launch Set for Oct 12 at the Paris Motor Show")

 ## XPENG Launches Its Next-Gen AI Flagship SUV G9L in China, with Global Launch Set for Oct 12 at the Paris Motor Show

  XPENG announces that the G9L will be launched in 64 global markets,…

   [](https://thailandbusinessnews.net/press-release/neopace-g10-pro-ai-powered-3d-replay-golf-launch-monitor-now-crowdfunding-on-kickstarter/) ![NeoPace G10 Pro: AI-Powered 3D Replay Golf Launch Monitor, Now Crowdfunding on Kickstarter](https://i0.wp.com/mmx.prnasia.com/media/MS1990613/20260917033526EDT_image_1.jpg?resize=260%2C140&ssl=1 "NeoPace G10 Pro: AI-Powered 3D Replay Golf Launch Monitor, Now Crowdfunding on Kickstarter")

 ## NeoPace G10 Pro: AI-Powered 3D Replay Golf Launch Monitor, Now Crowdfunding on Kickstarter

  Powered by TrainerIQ™, NeoPace G10 Pro combines a Triple-Cam + 24GHz Doppler…
<!-- Performance optimized by Docket Cache: https://wordpress.org/plugins/docket-cache -->
